Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,490 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Arginine reprograms metabolism in liver cancer via RBM39.
Mossmann D, Müller C, Park S, Ryback B, Colombi M, Ritter N, Weißenberger D, Dazert E, Coto-Llerena M, Nuciforo S, Blukacz L, Ercan C, Jimenez V, Piscuoglio S, Bosch F, Terracciano LM, Sauer U, Heim MH, Hall MN. Mossmann D, et al. Among authors: bosch f. Cell. 2023 Nov 9;186(23):5068-5083.e23. doi: 10.1016/j.cell.2023.09.011. Epub 2023 Oct 6. Cell. 2023. PMID: 37804830 Free PMC article.
CDK4 is an essential insulin effector in adipocytes.
Lagarrigue S, Lopez-Mejia IC, Denechaud PD, Escoté X, Castillo-Armengol J, Jimenez V, Chavey C, Giralt A, Lai Q, Zhang L, Martinez-Carreres L, Delacuisine B, Annicotte JS, Blanchet E, Huré S, Abella A, Tinahones FJ, Vendrell J, Dubus P, Bosch F, Kahn CR, Fajas L. Lagarrigue S, et al. Among authors: bosch f. J Clin Invest. 2016 Jan;126(1):335-48. doi: 10.1172/JCI81480. Epub 2015 Dec 14. J Clin Invest. 2016. PMID: 26657864 Free PMC article.
CDK4 is an essential insulin effector in adipocytes.
Lagarrigue S, Lopez-Mejia IC, Denechaud PD, Escoté X, Castillo-Armengol J, Jimenez V, Chavey C, Giralt A, Lai Q, Zhang L, Martinez-Carreres L, Delacuisine B, Annicotte JS, Blanchet E, Huré S, Abella A, Tinahones FJ, Vendrell J, Dubus P, Bosch F, Kahn CR, Fajas L. Lagarrigue S, et al. Among authors: bosch f. J Clin Invest. 2023 Mar 15;133(6):e170315. doi: 10.1172/JCI170315. J Clin Invest. 2023. PMID: 36919703 Free PMC article. No abstract available.
CDK4 is an essential insulin effector in adipocytes.
Lagarrigue S, Lopez-Mejia IC, Denechaud PD, Escoté X, Castillo-Armengol J, Jimenez V, Chavey C, Giralt A, Lai Q, Zhang L, Martinez-Carreres L, Delacuisine B, Annicotte JS, Blanchet E, Huré S, Abella A, Tinahones FJ, Vendrell J, Dubus P, Bosch F, Kahn CR, Fajas L. Lagarrigue S, et al. Among authors: bosch f. J Clin Invest. 2022 Jul 1;132(13):e162359. doi: 10.1172/JCI162359. J Clin Invest. 2022. PMID: 35775487 Free PMC article. No abstract available.
[Management of Injuries to the Parenchymal Abdominal Organs].
Schild-Suhren S, Yilmaz E, Biggemann L, Seif A, Torsello GF, Uhlig A, Ghadimi M, Bösch F. Schild-Suhren S, et al. Among authors: bosch f. Zentralbl Chir. 2024 Apr 29. doi: 10.1055/a-2301-7951. Online ahead of print. Zentralbl Chir. 2024. PMID: 38684170 German.
Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma.
Crochet G, Iacoboni G, Couturier A, Bachy E, Iraola-Truchuelo J, Gastinne T, Cartron G, Fradon T, Lesne B, Kwon M, Gounot R, Martínez-Cibrian N, Castilla-Llorente C, Abrisqueta P, Guerreiro M, Sarkozy C, Aspa-Cilleruelo JM, Camus V, Guidez S, Chauchet A, Deconinck E, Bouabdallah K, Bosch F, Barba P, Morschhauser F, Houot R. Crochet G, et al. Among authors: bosch f. Blood. 2024 Apr 24:blood.2024024526. doi: 10.1182/blood.2024024526. Online ahead of print. Blood. 2024. PMID: 38657242
Germline assessment for alloHSCT candidates over 50 years: A 'Fast-Track' screening in myeloid neoplasms.
Torres-Esquius S, Beas F, Chen-Liang TH, Pomares H, Santiago M, Varela ND, Liquori A, Hernandez F, Xicoy B, Hermosín L, Arnan M, Tazón-Vega B, Blanco A, Cervera J, Diez-Campelo M, Lozano ML, Valcárcel D, Bosch F, Montoro MJ, Jerez A; GESMD centres. Torres-Esquius S, et al. Among authors: bosch f. Br J Haematol. 2024 Apr 19. doi: 10.1111/bjh.19460. Online ahead of print. Br J Haematol. 2024. PMID: 38639421
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study.
Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon SS, Yoon DH, Matasar MJ, Bosch F, Kim WS, Nastoupil LJ, Flinn IW, Shadman M, Diefenbach C, Cheah CY, Ma CY, Huang H, Kwan A, Wei MC, Yin S, Bartlett NL. Budde LE, et al. Among authors: bosch f. J Clin Oncol. 2024 Mar 28:JCO2302329. doi: 10.1200/JCO.23.02329. Online ahead of print. J Clin Oncol. 2024. PMID: 38547425
1,490 results